Related Experiment Video
Updated: May 5, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
DNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells
Ran Zhao1, Chunhua Han, Eric Eisenhauer
1Department of Radiology, The Ohio State University, Room 1014 BRT, 460 W. 12th Avenue, Columbus, OH 43210. qi-en.wang@osumc.edu.
Unlabelled:
Elevated expression of the antiapoptotic factor Bcl-2 is believed to be one of the contributing factors to an increased relapse rate associated with multiple cisplatin-resistant cancers. DNA damage-binding protein complex subunit 2 (DDB2) has recently been revealed to play an important role in sensitizing human ovarian cancer cells to cisplatin-induced apoptosis through the downregulation of Bcl-2, but the underlying molecular mechanism remains poorly defined. Here, it is report that DDB2 functions as a transcriptional repressor for Bcl-2 in combination with DDB1. Quantitative ChIP and EMSA analysis revealed that DDB2 binds to a specific cis-acting element at the 5'-end of Bcl-2 P1 promoter. Overexpression of DDB2 resulted in marked losses of histone H3K9,14 acetylation along the Bcl-2 promoter and enhancer regions, concomitant with a local enrichment of HDAC1 to the Bcl-2 P1 core promoter in ovarian cancer cells. Coimmunoprecipitation and in vitro binding analyses identified a physical interaction between DDB1 and HDAC1, whereas downregulation of HDAC1 significantly enhanced Bcl-2 promoter activity. Finally, in comparison with wild-type DDB2, mutated DDB2, which is unable to repress Bcl-2 transcription, mediates a compromised apoptosis upon cisplatin treatment. Taken together, these data support a model wherein DDB1 and DDB2 cooperate to repress Bcl-2 transcription. DDB2 recognizes and binds to the Bcl-2 P1 promoter, and HDAC1 is recruited through the DDB1 subunit associated with DDB2 to deacetylate histone H3K9,14 across Bcl-2 regulatory regions, resulting in suppressed Bcl-2 transcription.
Implications:
Increasing the expression of DDB complex may provide a molecular strategy for cancer therapy.
Insights
DNA damage-binding protein complex subunit 2 (DDB2) represses Bcl-2 transcription with DDB1, sensitizing ovarian cancer cells to cisplatin. This mechanism involves DDB2 binding the Bcl-2 promoter and recruiting HDAC1 to reduce acetylation, offering a potential cancer therapy strategy.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Elevated Bcl-2 expression contributes to cisplatin resistance in multiple cancers.
- DNA damage-binding protein complex subunit 2 (DDB2) sensitizes ovarian cancer cells to cisplatin via Bcl-2 downregulation.
- The precise molecular mechanism of DDB2's action on Bcl-2 remains unclear.
Purpose of the Study:
- To elucidate the molecular mechanism by which DDB2 represses Bcl-2 transcription.
- To investigate the role of DDB1 and histone deacetylase 1 (HDAC1) in DDB2-mediated Bcl-2 regulation.
- To determine the functional significance of DDB2-mediated repression of Bcl-2 in cisplatin-induced apoptosis.
Main Methods:
- Quantitative ChIP and EMSA assays to assess DDB2 binding to the Bcl-2 promoter.
- Analysis of histone acetylation (H3K9,14) and HDAC1 enrichment at Bcl-2 regulatory regions.
- Coimmunoprecipitation and in vitro binding assays to detect protein-protein interactions.
- Functional studies using wild-type and mutated DDB2 in cisplatin-treated ovarian cancer cells.
Main Results:
- DDB2 functions as a transcriptional repressor of Bcl-2 in conjunction with DDB1.
- DDB2 directly binds to a specific element within the Bcl-2 P1 promoter.
- DDB2 overexpression reduces histone H3K9,14 acetylation and enriches HDAC1 at Bcl-2 promoter/enhancer regions.
- DDB1 interacts with HDAC1, and HDAC1 downregulation increases Bcl-2 promoter activity.
- Mutated DDB2, unable to repress Bcl-2, results in compromised cisplatin-induced apoptosis.
Conclusions:
- DDB1 and DDB2 cooperate to repress Bcl-2 transcription by recruiting HDAC1 to deacetylate histone H3K9,14, suppressing Bcl-2 expression.
- This mechanism highlights DDB2's role in overcoming cisplatin resistance.
- Enhancing DDB complex expression presents a potential molecular strategy for cancer therapy.
More Related Videos
09:14Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
13:10Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay
Published on: June 9, 2017
Related Concept Videos
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Abnormal Proliferation
DNA Helicases